menu
    • menu
    [{"orgOrder":0,"company":"Imugene","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0.23000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Kincell Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"Precision BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0.66000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.66000000000000003,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"NeoImmuneTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Collaboration","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"4","companyTruncated":"Imugene \/ Imugene"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"CF33-CD19","moa":"CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Celularity","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Collaboration","leadProduct":"CF33-CD19","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Celularity","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Celularity"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Blinatumomab","moa":"||CD19","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Merck & Co"},{"orgOrder":0,"company":"Imugene","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Avelumab","moa":"||HER2","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Merck & Co","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Merck & Co"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"IMU-201","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2021","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PD1-Vaxx","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"CF33-expressing hNIS","moa":"Tumor cell","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"City of Hope","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Inapplicable","leadProduct":"CF33-hNIS","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Imugene \/ City of Hope","highestDevelopmentStatusID":"6","companyTruncated":"Imugene \/ City of Hope"},{"orgOrder":0,"company":"Imugene","sponsor":"RenovoRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"Imugene \/ Imugene"}]

    Find Clinical Drug Pipeline Developments & Deals by Imugene

    Menu

    Imugene

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Imugene

                            Australia arrow
                            PackExpo
                            Not Confirmed

                            Imugene

                            Australia arrow
                            PackExpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Precision BioSciences

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Precision Receives $13M in Proceeds from Imugene Convertible Notes

                            Details : Imugene assumed global rights to azer-cel for cancer, the ongoing clinical execution for PBCAR0191 (azercabtagene zapreleucel) in LBCL patients who have relapsed following autologous CAR T treatment.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $21.0 million

                            September 03, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Precision BioSciences

                            Deal Size : $227.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Phase 1b Trial for Blood Cancer

                            Details : Azercabtagene Zapreleucel (azer-cel), an allogeneic CD19 CAR T cell therapy being investigated relapsed/refractory diffuse large B cell lymphoma.

                            Product Name : Azer-Cel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 03, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Imugene

                            Australia arrow
                            Luxepack
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Luxepack
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Kincell Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Imugene and Kincell Announce Strategic Manufacturing and Process Development Partnership

                            Details : Under the agreement, Kincell will manufacture Imugene’s Azer-cel (azercabtagene zapreleucel), an off-the-shelf (allogeneic) cell therapy CAR T drug, to support ongoing clinical trials.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 16, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Kincell Bio

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

                            Details : onCARlytics (CF33-CD19) is a novel CD19 oncolytic virotherapy drug candidate, which is being evaluated for the treatment of patients with advanced solid tumors.

                            Product Name : onCARlytics

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 11, 2024

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            MaxCyte Signs License with Imugene To Advance Cancer Immunotherapy Programs

                            Details : Imugene has obtained commercial rights to use MaxCyte’s technology and ExPERT platform to support azer-cel, a potential allogeneic CD19 CAR T product candidate for blood cancer treatment.

                            Product Name : Azer-Cel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 23, 2024

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : MaxCyte

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alpha

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : NeoImmuneTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            NeoImmuneTech and Imugene Enter into Strategic Research Collaboration to Improve Cancer Treatments

                            Details : The collaboration aims to evaluate Imugene's allogeneic CAR T, azer-cel, in combination with NIT's proprietary immune T cell amplifier "Fc-fused recombinant human interleukin-7", NT-I7, for the treatment of cancer.

                            Product Name : Azer-Cel

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            December 11, 2023

                            Lead Product(s) : Azercabtagene Zapreleucel,Efineptakin Alpha

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : NeoImmuneTech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-CD19

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of onCARlytics (CF33-CD19) in Combination With Blinatumomab in Adults With Advanced or Metastatic Soli...

                            Details : CF33-CD19 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 02, 2023

                            Lead Product(s) : CF33-CD19

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Precision BioSciences

                            Deal Size : $662.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Precision BioSciences Completes Strategic Transaction with Imugene for Azer-Cel in Cancer

                            Details : Imugene gains global rights to PBCAR0191 (azercabtagene zapreleucel), Precision’s lead allogeneic CAR T candidate, for cancer. Imugene will assume ongoing trial for azer-cel in the large B-cell lymphoma and has an option to develop up to three other ca...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : $29.0 million

                            August 15, 2023

                            Lead Product(s) : Azercabtagene Zapreleucel,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Precision BioSciences

                            Deal Size : $662.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : RenovoRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arteria...

                            Details : The collaboration aims to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of difficult-to-access tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 20, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : RenovoRx

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed

                            Imugene

                            Australia arrow
                            Organic Process R&D
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Clears Imugene IND To Commence onCARlytics First-In-Class Clinical Study

                            Details : onCARlytics (CF33-CD19, HOV4) is a live, attenuated oncolytic orthopox (vaccinia) virus engineered to encode a truncated human CD19 transgene, resulting in expression of de novo CD19 at the tumour cell surface before virus-mediated tumour cell lysis.

                            Product Name : onCARlytics

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2023

                            Lead Product(s) : CF33-CD19,Blinatumomab

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth